Cargando…
Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643943/ https://www.ncbi.nlm.nih.gov/pubmed/37969378 http://dx.doi.org/10.21037/tcr-23-1279 |
| _version_ | 1785147177480224768 |
|---|---|
| author | Elias, Roy Antonarakis, Emmanuel S. |
| author_facet | Elias, Roy Antonarakis, Emmanuel S. |
| author_sort | Elias, Roy |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10643943 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106439432023-11-15 Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? Elias, Roy Antonarakis, Emmanuel S. Transl Cancer Res Editorial Commentary AME Publishing Company 2023-10-03 2023-10-31 /pmc/articles/PMC10643943/ /pubmed/37969378 http://dx.doi.org/10.21037/tcr-23-1279 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Elias, Roy Antonarakis, Emmanuel S. Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title_full | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title_fullStr | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title_full_unstemmed | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title_short | Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? |
| title_sort | rucaparib for metastatic castration-resistant prostate cancer: did triton3 deliver a trifecta? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643943/ https://www.ncbi.nlm.nih.gov/pubmed/37969378 http://dx.doi.org/10.21037/tcr-23-1279 |
| work_keys_str_mv | AT eliasroy rucaparibformetastaticcastrationresistantprostatecancerdidtriton3deliveratrifecta AT antonarakisemmanuels rucaparibformetastaticcastrationresistantprostatecancerdidtriton3deliveratrifecta |